The Space Launch System is facing fresh calls for cancelation, but still has a key role to play in NASA’s return to the moon.
On Wednesday, Sellas Life Sciences Group Inc (SLS) stock saw a decline, ending the day at $1.17 which represents a decrease of $-0.03 or -2.50% from the prior close of $1.2. The stock opened at $1.24 ...
Eric Berger is the Ars Technica, senior space editor and author of Reentry, a book about the behind the scenes SpaceX ...
What’s next for NASA’s giant moon rocket? NASA’s huge lunar rocket, the Space Launch System (SLS), might be in trouble. As ...
The NASA-funded Space Launch System (SLS), the massive rocket slated to send the Artemis 2 crew around the moon in 2025, is ...
On the second anniversary of its maiden launch, relive the moment NASA's mega moon soared skyward, sending the Orion ...
Germany will send two IRIS-T air defense systems to Ukraine by the end of the year, according to German Major General ...
SELLAS Life Sciences (SLS) announced data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective ...
SLS Baha Mar unveils redesigned rooms blending luxury, Bahamian culture, and practicality for families and groups, enhancing ...